Abstract Background Brain metastases from renal cell carcinoma (RCC) remain a major cause of morbidity and mortality, yet the genomic features associated with metastatic dissemination remain poorly understood. Methods Whole-exome sequencing was performed on 72 RCC brain metastasis samples with matched normal. To identi...
Betul Gok Yavuz, E. Hasanov· The Oncologist· 0 citations
Abstract Background Oligometastatic clear-cell renal cell carcinoma (ccRCC) is a biologically distinct, often indolent state where metastasis-directed therapy, including metastasectomy or SBRT, provides durable local control and delays systemic therapy. Randomized prospective trial evidence demonstrates a survival bene...
Abhirami Das, S. Balkhi, A. Mitta et al.· The Oncologist· 0 citations
Brain metastases (BM) from renal cell carcinoma (RCC) significantly affect survival, and disease-specific prognostic tools for patients undergoing stereotactic radiosurgery (SRS) remain limited. We aimed to identify prognostic factors and develop an interpretable machine learning (ML) model for individualized ris...
S. Ozgul, Melis Parabas, Peng Li et al.· Neuro-Oncology Practice· 0 citations
A robust machine learning framework integrating genomic mutations and copy number alterations to predict survival in BM patients demonstrates stable performance and effective risk stratification in an independent cohort, supporting its potential clinical utility for prognostic assessment and precision oncology applicat...
M. I. Ali, Z. Majeed, Peng Li et al.· Neuro-Oncology Advances· 0 citations
RCC BM represents a biologically distinct tumor entity shaped by neural adaptation, metabolic reprogramming, and immune dysfunction, and supported clinical trials approval testing lenvatinib plus pembrolizumab and zanzalitinib in RCC BM patients.
M. I. Ali, Z. Akpinar, Jose A. Ovando-Ricardez et al.· Neuro-Oncology Advances· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
